세계의 만성질환 관리 치료제·기기 기술 시장 규모는 2023년 6,750억 달러, 2024년 7,263억 달러에서 예측 기간 중 8.1%의 CAGR로 추이하며, 2029년에는 1조 1,000억 달러 규모로 성장할 것으로 예측됩니다.
의약품 및 생물제제 부문은 2024년 5,135억 달러에서 8.0%의 CAGR로 추이하며, 2029년에는 7,540억 달러로 성장할 것으로 예측됩니다. 또한 디지털 치료제 부문은 2024년 646억 달러에서 11.6%의 CAGR로 추이하며, 2029년에는 1,117억 달러로 성장할 것으로 예측됩니다.
세계의 만성질환 관리 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 법규제 환경, 신규 기술 및 기술개발의 동향, 시장 규모 추이·예측, 각종 구분·지역별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 개요
제2장 시장 개요
- 시장 분석
- 규제의 배경
- Chronic Disease Management Act of 2021(CDMA)
- 만성질환용 의료기기에 관한 규제 프레임워크 : 지역별
- 의약품 규제 제도 : 지역별
- 가격결정과 상환의 배경
- 의료기기의 가격 설정과 상환 : 지역별
- 의약품의 가격 설정과 상환 : 지역별
제3장 시장 역학
- 개요
- 시장 성장 촉진요인
- 세계의 고령화
- 만성질환의 증가
- 기술의 진보
- 정부 구상과 자금
- 시장 성장 억제요인
- 치료비의 상승
- 특허 만료와 제품수명주기 단축
- 의약품, 의료기기, 소프트웨어 애플리케이션에 관한 규제 문제
- 저소득 지역에서의 액세스상 제약
- 시장이 해결해야 할 과제
- 복약 불준수
- 규제상 과제
- 디지털 헬스 애플리케이션의 과제
- 시장 기회
- 디지털 치료제
- 주요 기업에 의한 강력한 R&D 구상
제4장 시장 세분화 분석
- 세분화 내역
- 시장 분석 : 제품 유형별
- 의약품 및 생물제제
- 의료기기
- 디지털 치료제
- 시장 분석 : 용도별
- 종양성 질환
- 대사장애
- 심혈관질환
- 면역 질환
- 호흡기질환
- 근골격 장애
- 만성 위장질환
- 신경질환
- 정신 질환
- 기타
- 시장 분석 : 최종사용자별
- 홈케어
- 병원 등
- 지역적 내역
- 시장 분석 : 지역별
- 북미
- 유럽
- 아시아태평양
- 기타 지역
제5장 새로운 동향과 기술
- 개요
- 모바일 헬스 기술
- 만성질환 관리에서의 AI·기계학습·딥러닝
- 원격 환자 모니터링 디바이스
- 디지털 치료제
- 바이오 웨어러블 기술
- 글루코오스 센서 콘택트렌즈
- 신규 의약품 및 의료기기의 최근 승인과 발매
제6장 ESG의 동향
- 만성질환 관리 업계에서 ESG
- ESG 리스크 평가
- BCC Research에 의한 견해
제7장 경쟁 구도
- M&A·제휴
- 특허 분석
- 특허 리뷰 : 양수 국가별
- 특허 리뷰 : 연별
- 기업 점유율 분석
- 전략적 제휴
제8장 부록
- 조사 방법
- 전시
- 약어
- 기업 개요
- ABBOTT
- AMGEN INC.
- ASTRAZENECA
- BOSTON SCIENTIFIC CORP.
- BRISTOL-MYERS SQUIBB CO.
- F. HOFFMANN-LA ROCHE LTD.
- GSK PLC.
- JOHNSON & JOHNSON SERVICES INC.
- MEDTRONIC
- PFIZER INC.
KSA
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
The global market for pharmaceutical drugs and biologics for chronic disease management is projected to grow from $513.5 billion in 2024 to $754.0 billion by 2029, at a CAGR of 8.0% from 2024 through 2029.
The global market for digital therapeutics for chronic disease management is projected to grow from $64.6 billion in 2024 to $111.7 billion by 2029, at a CAGR of 11.6% from 2024 through 2029.
Report Scope
Chronic disease management encompasses drugs and medical device-based techniques. This report can serve as an analytical business tool to evaluate the global market for therapeutics and advanced device technologies for chronic disease management.
This report analyzes market trends with data from 2023, estimates for 2024 and projections of CAGRs through 2029. It evaluates the market potential for chronic disease management and provides an analysis of the competitive landscape. The report covers the market's drivers, restraints and opportunities, as well as the market shares of leading companies.
The market is segmented into product type, application, end user, and geographic region. Product segments include pharmaceuticals and biologics (drugs and biologics), medical devices (traditional and wearable devices) and digital therapeutics. Application areas (disease categories) are cancer, metabolic disorders, musculoskeletal disorders, cardiovascular conditions, immunological disorders, gastrointestinal disorders, respiratory diseases, neurological conditions, psychiatric conditions, and others. End users are categorized into hospitals and other facilities and home care. The global market is segmented into the regions of North America, Europe, Asia-Pacific, and the Rest of the World (RoW). This analysis also includes broken down by country.
Report Includes
- 106 data tables and 39 additional tables
- Analyses of global market trends, with historic market revenue data (sales figures) from 2021 to 2022, estimates for 2023, forecast for 2024, and projected CAGRs through 2029
- Estimates of the current market size and revenue prospects of the global market, along with a market share analysis by product type, application, end user, and region
- Analysis of the market dynamics, technological advances, regulations, and the macroeconomic factors influencing the market
- A look into the current state of chronic diseases and disorders, with an emphasis on advance needle-free drug delivery technologies, diagnostic methods, and smart device technologies that support chronic disease management
- Identification of promising new drugs, biologics, and emerging device technologies still in the development and testing stages
- A look at the regulatory structure for pharmaceuticals and medical devices, pricing and reimbursement structure, marketed and pipeline products and their potential for commercialization
- A look at the recent patent grants
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, ESG score analysis, and the ESG practices of leading companies
- Analysis of the industry structure, including company market shares, strategic alliances, M&A activity and a venture funding outlook
- Profiles of market leaders, including Abbott, Bristol Myers Squibb Co., F. Hoffmann-La Roche Ltd., Pfizer Inc., and Johnson & Johnson Services Inc.
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- What's New in This Update?
- Market Summary
Chapter 2 Market Overview
- Market Insights
- Regulatory Background
- Chronic Disease Management Act of 2021 (CDMA)
- Regional Regulatory Frameworks for Chronic Disease Medical Devices
- Regulatory Systems for Pharmaceuticals, by Region
- Pricing and Reimbursement Background
- Pricing and Reimbursement for Medical Devices, by Region
- Pricing and Reimbursement for Pharmaceuticals, by Region
Chapter 3 Market Dynamics
- Overview
- Market Drivers
- Growing Aging Population Worldwide
- Growing Prevalence of Chronic Diseases
- Technological Advances
- Government Initiatives and Funding
- Market Restraints
- High Cost of Treatments
- Patent Expiry and Shorter Product Life Cycles
- Regulatory Issues for Drugs, Medical Devices and Software Applications
- Limited Access in Low-Income Regions
- Market Challenges
- Medication Nonadherence
- Regulatory Challenges
- Challenges with Digital Health Applications
- Market Opportunities
- Digital Therapeutics
- Strong Research and Development Initiatives from Key Market Players
Chapter 4 Market Segmentation Analysis
- Segmentation Breakdown
- Market Analysis, by Product Type
- Pharmaceutical Drugs and Biologics
- Medical Devices
- Digital Therapeutics
- Market Analysis, by Application
- Oncological Diseases
- Metabolic Disorders
- Cardiovascular Diseases
- Immunological Disorders
- Respiratory Diseases
- Musculoskeletal Disorders
- Chronic Gastrointestinal Diseases
- Neurological Diseases
- Psychiatric Disorders
- Other Applications
- Market Analysis, by End User
- Home Care
- Hospitals and Others
- Geographic Breakdown
- Market Analysis, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 5 Emerging Trends and Technologies
- Overview
- Mobile Health Technology
- AI, Machine Learning, and Deep Learning in Chronic Care Management
- Remote Patient Monitoring Devices
- Digital Therapeutics
- Biowearable Technology
- Glucose-Sensing Contact Lenses
- Recent Approvals and Launches of Novel Drug and Device Products
Chapter 6 ESG Developments
- ESG in the Chronic Disease Management Industry
- ESG Risk Ratings
- BCC Research Viewpoint
Chapter 7 Competitive Landscape
- Mergers, Acquisitions and Collaborations
- Patent Analysis
- Patent Review, by Assignee Country
- Patent Review, by Year
- Company Share Analysis
- Strategic Alliances
Chapter 8 Appendix
- Methodology
- Sources
- Abbreviations
- Company Profiles
- ABBOTT
- AMGEN INC.
- ASTRAZENECA
- BOSTON SCIENTIFIC CORP.
- BRISTOL-MYERS SQUIBB CO.
- F. HOFFMANN-LA ROCHE LTD.
- GSK PLC.
- JOHNSON & JOHNSON SERVICES INC.
- MEDTRONIC
- PFIZER INC.
